- Home
- AIIOW vs CMMB Comparison
AIIOW vs CMMB Comparison
Compare AIIOW & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIIOW
- CMMB
- Stock Information
- Founded
- AIIOW N/A
- CMMB 2004
- Country
- AIIOW United Arab Emirates
- CMMB Israel
- Employees
- AIIOW N/A
- CMMB N/A
- Industry
- AIIOW Auto Manufacturing
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- AIIOW Industrials
- CMMB Health Care
- Exchange
- AIIOW Nasdaq
- CMMB Nasdaq
- Market Cap
- AIIOW 19.0M
- CMMB 22.0M
- IPO Year
- AIIOW N/A
- CMMB N/A
- Fundamental
- Price
- AIIOW $0.06
- CMMB $3.09
- Analyst Decision
- AIIOW
- CMMB Strong Buy
- Analyst Count
- AIIOW 0
- CMMB 2
- Target Price
- AIIOW N/A
- CMMB $26.50
- AVG Volume (30 Days)
- AIIOW N/A
- CMMB 136.3K
- Earning Date
- AIIOW N/A
- CMMB 08-14-2025
- Dividend Yield
- AIIOW N/A
- CMMB N/A
- EPS Growth
- AIIOW N/A
- CMMB N/A
- EPS
- AIIOW N/A
- CMMB N/A
- Revenue
- AIIOW N/A
- CMMB N/A
- Revenue This Year
- AIIOW N/A
- CMMB N/A
- Revenue Next Year
- AIIOW N/A
- CMMB N/A
- P/E Ratio
- AIIOW N/A
- CMMB N/A
- Revenue Growth
- AIIOW N/A
- CMMB N/A
- 52 Week Low
- AIIOW N/A
- CMMB $2.99
- 52 Week High
- AIIOW N/A
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- AIIOW N/A
- CMMB 24.58
- Support Level
- AIIOW N/A
- CMMB $2.99
- Resistance Level
- AIIOW N/A
- CMMB $3.86
- Average True Range (ATR)
- AIIOW 0.00
- CMMB 0.26
- MACD
- AIIOW 0.00
- CMMB -0.02
- Stochastic Oscillator
- AIIOW 0.00
- CMMB 8.85
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.